UBR1
Basic information
Region (hg38): 15:42942897-43106113
Links
Phenotypes
GenCC
Source:
- Johanson-Blizzard syndrome (Definitive), mode of inheritance: AR
- Johanson-Blizzard syndrome (Strong), mode of inheritance: AR
- Johanson-Blizzard syndrome (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Johanson-Blizzard syndrome | AR | Audiologic/Otolaryngologic; Cardiovascular; Endocrine; Gastrointestinal; Hematologic | Medical treatment of exocrine pancreatic insufficiency can be beneficial; Awareness of cardiovascular manifestastions (which can include structural malformations as well as cardiomyopathy) can allow early diagnosis and treatment; As the condition can include congenital deafness, early recognition and treatment of hearing impairment may improve outcomes, including speech and language development; Treatment of endocrine manifestations, such as hypothyroidism, growth hormone deficiency, and diabetes mellitus, can be beneficial; Severe anemia requiring transfusions has been described, and awareness may allow prompt diagnosis and treatment | Audiologic/Otolaryngologic; Craniofacial; Dental; Dermatologic; Cardiovascular; Endocrine; Gastrointestinal; Hematologic; Neurologic; Ophthalmologic | 5171616; 728568; 474625; 4050852; 2645405; 12535044; 12725595; 14647752; 15379429; 16311597; 16632090; 17378628; 18553553; 19058315; 19006206; 19717322; 20556423; 21931868; 20556422; 21429315; 21711208; 22072859; 23463671; 23778732; 24052374 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (24 variants)
- Johanson-Blizzard syndrome (3 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the UBR1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 335 | 22 | 358 | |||
missense | 109 | 34 | 155 | |||
nonsense | 16 | 16 | ||||
start loss | 0 | |||||
frameshift | 10 | 12 | ||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 17 | 19 | ||||
splice region | 2 | 3 | 84 | 5 | 94 | |
non coding | 263 | 52 | 317 | |||
Total | 27 | 25 | 112 | 632 | 82 |
Highest pathogenic variant AF is 0.0000197
Variants in UBR1
This is a list of pathogenic ClinVar variants found in the UBR1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
15-42945005-T-C | Benign (Jun 19, 2021) | |||
15-42945216-C-T | Benign (May 16, 2021) | |||
15-42945332-C-T | Likely benign (Nov 28, 2023) | |||
15-42945358-A-G | Likely benign (Aug 31, 2023) | |||
15-42945359-C-A | Uncertain significance (Oct 13, 2023) | |||
15-42945365-A-G | Likely benign (May 22, 2023) | |||
15-42945371-C-T | Benign (Jan 15, 2024) | |||
15-42945374-T-C | not specified | Benign (Jan 31, 2024) | ||
15-42945377-G-C | UBR1-related disorder • Inborn genetic diseases | Conflicting classifications of pathogenicity (Jan 31, 2024) | ||
15-42945385-C-A | Inborn genetic diseases | Uncertain significance (Oct 12, 2022) | ||
15-42945392-T-C | Likely benign (Feb 03, 2023) | |||
15-42945396-A-G | Inborn genetic diseases | Uncertain significance (Nov 03, 2022) | ||
15-42945401-G-A | Likely benign (Jan 29, 2024) | |||
15-42945432-C-T | Inborn genetic diseases | Uncertain significance (Oct 05, 2022) | ||
15-42945434-A-G | Likely benign (Nov 15, 2023) | |||
15-42945443-A-C | UBR1-related disorder | Likely benign (Sep 08, 2023) | ||
15-42945444-C-T | Microcephaly • UBR1-related disorder | Conflicting classifications of pathogenicity (Jan 31, 2024) | ||
15-42945446-A-G | Likely benign (Oct 04, 2023) | |||
15-42945449-T-C | Likely benign (Dec 19, 2023) | |||
15-42945451-A-C | Uncertain significance (Aug 25, 2021) | |||
15-42945464-G-A | Likely benign (Nov 22, 2023) | |||
15-42945466-C-T | Uncertain significance (-) | |||
15-42945474-T-A | Likely benign (Jan 21, 2024) | |||
15-42945478-G-T | Likely benign (Dec 06, 2023) | |||
15-42945478-GA-G | Benign (Mar 15, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
UBR1 | protein_coding | protein_coding | ENST00000290650 | 47 | 163217 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00549 | 0.995 | 125704 | 0 | 44 | 125748 | 0.000175 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.40 | 714 | 918 | 0.777 | 0.0000463 | 11593 |
Missense in Polyphen | 146 | 279.14 | 0.52303 | 3529 | ||
Synonymous | -0.546 | 319 | 307 | 1.04 | 0.0000155 | 3135 |
Loss of Function | 7.15 | 27 | 107 | 0.253 | 0.00000531 | 1329 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000478 | 0.000478 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000925 | 0.0000924 |
European (Non-Finnish) | 0.000187 | 0.000185 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000229 | 0.000229 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. May be involved in pancreatic homeostasis. Binds leucine and is a negative regulator of the leucine-mTOR signaling pathway, thereby controlling cell growth. {ECO:0000269|PubMed:15548684, ECO:0000269|PubMed:16311597, ECO:0000269|PubMed:20298436, ECO:0000269|PubMed:20835242}.;
- Disease
- DISEASE: Johanson-Blizzard syndrome (JBS) [MIM:243800]: This disorder includes congenital exocrine pancreatic insufficiency, multiple malformations such as nasal wing aplasia, and frequent mental retardation. Pancreas of individuals with JBS do not express UBR1 and show intrauterine-onset destructive pancreatitis. {ECO:0000269|PubMed:16311597, ECO:0000269|PubMed:21931868, ECO:0000269|PubMed:22072859, ECO:0000269|PubMed:24599544, ECO:0000269|PubMed:26149651}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- protein ubiquitylation;Immune System;Adaptive Immune System;Antigen processing: Ubiquitination & Proteasome degradation;Class I MHC mediated antigen processing & presentation
(Consensus)
Recessive Scores
- pRec
- 0.194
Intolerance Scores
- loftool
- 0.598
- rvis_EVS
- -0.63
- rvis_percentile_EVS
- 16.81
Haploinsufficiency Scores
- pHI
- 0.655
- hipred
- N
- hipred_score
- 0.488
- ghis
- 0.607
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.775
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ubr1
- Phenotype
- growth/size/body region phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); digestive/alimentary phenotype;
Gene ontology
- Biological process
- protein ubiquitination;negative regulation of TOR signaling;cellular response to leucine;ubiquitin-dependent protein catabolic process via the N-end rule pathway
- Cellular component
- ubiquitin ligase complex;proteasome complex;cytoplasm;cytosol
- Molecular function
- protein binding;zinc ion binding;ubiquitin protein ligase activity;leucine binding